Eledon Pharmaceuticals Inc(ELDN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:57 PM ET (Korea 10/31 08:57)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.99 | Insider Own | 1.02% | Shs Outstand | 80.9M | Perf Week | 20.43% |
| Market Cap | 0.23B | Forward P/E | - | EPS next Y | 12.63% | Insider Trans | - | Shs Float | 80.4M | Perf Month | 13.76% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | -0.19 | Inst Own | 62.56% | Short Float | 9.82% | Perf Quarter | -19.24% |
| Income | -0.10B | P/S | - | EPS this Y | -82.69% | Inst Trans | 6.32% | Short Ratio | 8.5 | Perf Half Y | -24.93% |
| Sales | 0.00B | P/B | 6.79 | EPS next 5Y | -17.33% | ROA | -72.74% | Short Interest | 7.90M | Perf YTD | 83.44% |
| Book/sh | 0.41 | P/C | 2.54 | EPS past 3/5Y | 55.1% 48.72% | ROE | -110.71% | 52W High | -39.78% ($4.60) | Perf Year | -36.32% |
| Cash/sh | 1.09 | P/FCF | - | Sales past 3/5Y | - | ROIC | -136.67% | 52W Low | 105.19% ($1.35) | Perf 3Y | 75.32% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -1475.42% | Gross Margin | - | Volatility(W/M) | 12.96% 7.8% | Perf 5Y | -44.6% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.21 | Perf 10Y | -98.46% |
| Dividend Ex-Date | - | Quick Ratio | 7.9 | EPS Q/Q | -91.47% | Profit Margin | - | RSI (14) | 58.02 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.9 | Sales Q/Q | - | SMA20 | 15.02% ($2.41) | Beta | 0.98 | Target Price | $9.5 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/13 | SMA50 | 3.17% ($2.68) | Rel Volume | 1.36 | Prev Close | $3.04 |
| Employees | 33 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -70.89% - | SMA200 | -10.83% ($3.11) | Avg Volume(3M) | 0.93M | Price | $2.77 |
| IPO | 2014/9/17 | Option/Short | Yes/Yes | Trades | 4657 | Volume | 1,264,962 | Change | -8.88% |
🧬 This is a U.S. clinical-stage biotech company developing next-generation immune-suppressing antibody therapeutics designed to prevent long-term transplant rejection. Its lead candidate, tegoprubart, is an antibody that blocks the immune co-stimulatory pathway, and it is currently being evaluated in clinical trials across multiple indications, including kidney, islet cell, and liver transplants, as well as xenotransplantation.
Over the past 1 year, roughly in the middle
40% below its 1-year high.
Traded more than usual. That is 136% of its average volume.
ELDN has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -82.7% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -44.6%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 62.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #290 of 597 in the industry
Based on market cap of $225M.
VNDA#288 Vanda Pharmaceuticals Inc $229M PER - 
ACIU#289 AC Immune SA $226M PER - ELDN#290 Eledon Pharmaceuticals Inc $225M PER - 
SLGL#291 Sol-Gel Technologies Ltd $224M PER - 
KROS#292 Keros Therapeutics Inc $219M PER - 
FAQ
What kind of company is ELDN?
ELDN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ELDN?
The market cap of ELDN is approximately $225M, ranking 3,922 within its sector.
What is the 52-week high and low for ELDN?
ELDN has recorded a 52-week high of $4.60 and a low of $1.35.
